Soligenix and Silk Road sign deal for Behçet’s disease treatment rights
02 May 2023
Clinical ResultPhase 2License out/inDrug Approval
Preview
Source: Pharmaceutical Technology
Soligenix has the right to purchase the topical formulation. Credit: AdoreBeautyNZ from Pixabay.
Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients.
The firms did not divulge the terms of the deal.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Satralizumab in Demyelinating Diseases GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Cilnidipine + Tadalafil) in Raynauds Disease GlobalData
View all
BD is a rare multisystem inflammatory vasculitis, which currently has no treatment.
The disease is characterised by severe recurrent ulcers in the oral mucosa, skin, genitalia and eyes.
It is estimated to impact around 18,000 people in the US and 80,000 in Europe, while 1,000,000 people are living with the disease across the globe.
Soligenix reported that PTX was found to be more effective than colchicine in a Phase II proof-of-concept (POC) trial. BD patients were randomised to receive either standard-of-care colchicine therapy or colchicine in combination with topical PTX.
Patients applied the PTX mucoadhesive gel four times a day for up to 14 days for treating current mouth ulcers. They also used their standard colchicine regimen.
It was found that 83% of patients treated with PTX had index ulcer area shrinkage by day two, as against 19% of patients treated with only colchicine.
Meanwhile, pain scores were also reported to be reduced in patients receiving PTX. No serious adverse events were observed among the patients.
“General agreement amongst treating physicians is that current front-line treatment/management options, such as oral and topical steroids, are largely ineffective and have a number of potentially significant safety issues when used long-term.
“When transitioning to the more effective therapies, like biologics such as adalimumab and apremilast, the only approved treatment in BD, these longer-term safety concerns persist and are associated with a much higher financial burden to patients and/or payers in treating this lifelong condition.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.